Latest News
Category: News
News,
Telix advises that it has evaluated the Executive Order issued by the United States (U.S.) Government to implement a “Most-Favored Nation” (MFN) policy around drug pricing. Based on currently available information, there is a low likelihood of material impact to Telix’s...
Read more
Telix today announces that that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient...
Read more
News,
Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging...
Read moreNews,
Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in the Czech Republic by the...
Read more
News,
Telix announces its Annual General Meeting of shareholders to be held...
Read more
Telix announces its Annual General Meeting of shareholders to be held...
Read more
Join Telix this week at the 2025 The American Urological Association (AUA) Annual Meeting in Las Vegas,...
Read more
Telix announces its Annual General Meeting of shareholders to be held...
Read more
Telix announces its Annual General Meeting of shareholders to be held...
Read more
Telix today announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer), substantiating the patient benefit seen in the IPAX-1...
Read more